Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany.
<h4>Background</h4>The efficacy of the BioNTech-Pfizer BNT162b2 vaccination in the elderly (≥80 years) could not be fully assessed in the BioNTech-Pfizer trial due to low numbers in this age group. We aimed to evaluate the effectiveness of the BioNTech-Pfizer (BNT162b2) vaccine to preven...
Enregistré dans:
Auteurs principaux: | Delphina Gomes, Andreas Beyerlein, Katharina Katz, Gabriele Hoelscher, Uta Nennstiel, Bernhard Liebl, Klaus Überla, Rüdiger von Kries |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Public Library of Science (PLoS)
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/de9ecba25d754328ba676c3a14796db2 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany
par: Delphina Gomes, et autres
Publié: (2021) -
Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations
par: Shai Efrati, et autres
Publié: (2021) -
Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study
par: Rana Shibli, et autres
Publié: (2021) -
Immunogenicity of a BNT162b2 vaccine booster in health-care workers
par: Esther Saiag, et autres
Publié: (2021) -
What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?
par: Nicola Silvestris
Publié: (2021)